# NIMRAD (A Randomised Placebo-controlled Trial of Synchronous NIMorazole Versus RADiotherapy Alone in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Not Suitable for Synchronous Chemotherapy or Cetuximab)

> **NCT01950689** · PHASE3 · COMPLETED · sponsor: **The Christie NHS Foundation Trust** · enrollment: 338 (actual)

## Conditions studied

- Head and Neck Squamous Cell Carcinoma

## Interventions

- **DRUG:** Nimorazole
- **RADIATION:** Radiotherapy

## Key facts

- **NCT ID:** NCT01950689
- **Lead sponsor:** The Christie NHS Foundation Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09-11
- **Primary completion:** 2021-01-07
- **Final completion:** 2021-01-07
- **Target enrollment:** 338 (ACTUAL)
- **Last updated:** 2021-10-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01950689

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01950689, "NIMRAD (A Randomised Placebo-controlled Trial of Synchronous NIMorazole Versus RADiotherapy Alone in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Not Suitable for Synchronous Chemotherapy or Cetuximab)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01950689. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*